Fig. 2From: A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthmaFlow chart depicting reasons for exclusion of subjects and adverse events from final analysis. Half of the 22 screened subjects failed to meet inclusion or exclusion criteria. One enrolled subject withdrew after the initial period thus his data was excluded from the final analysis according to protocol. Adverse events that occurred before dosing or between periods were also excluded. Ultimately, ten subjects accounted for 280 adverse events in the final analysis. Abbreviations: AEs = adverse eventsBack to article page